Recombinant Interleukin‐1 Receptor Antagonist Is an Effective First‐Line Treatment Strategy in New‐Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA‐DRB1 Background and IL1RN Variants

Anakinra in patients with systemic juvenile idiopathic arthritis: long-term safety from the Pharmachild registry

(2022) Gabriella Giancane et al.   JOURNAL OF RHEUMATOLOGY

The Conundrum of Lung Disease and Drug Hypersensitivity‐like Reactions in Systemic Juvenile Idiopathic Arthritis

(2022) Bryce A. Binstadt et al.   Arthritis & Rheumatology

Association of atypical skin manifestations at the onset of systemic juvenile idiopathic arthritis with difficult-to-treat disease : a retrospective multicenter study.

(2022) Laurye-Anne Eveillard et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis

(2021) Remco Erkens et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles

(2021) Vivian E Saper et al.   ANNALS OF THE RHEUMATIC DISEASES

Common, intermediate and well‐documented HLA alleles in world populations: CIWD version 3.0.0

(2020) Carolyn K. Hurley et al.   HLA

Long-term outcomes and disease course of children with juvenile idiopathic arthritis in the ReACCh-Out cohort: a two-centre experience

(2020) Amieleena Chhabra et al.   RHEUMATOLOGY

Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019

(2020) Scott W. Canna et al.   Pediatric Rheumatology

New medications are needed for children with juvenile idiopathic arthritis

(2020) Hermine I Brunner et al.   Arthritis & Rheumatology

Early treatment and il1rn snps affect response to anakinra in systemic juvenile idiopathic arthritis

(2020) Manuela Pardeo et al.   Arthritis & Rheumatology

Next Generation Sequencing Characterizes HLA Diversity in a Registry Population from The Netherlands

(2019) Lihua Hou et al.   HLA

Treat-to-target using first-line recombinant interleukin-1 receptor antagonist monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study

(2019) Nienke M. ter Haar et al.   Arthritis & Rheumatology

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

(2019) Mia Glerup et al.   ARTHRITIS CARE & RESEARCH

Emergent high fatality lung disease in systemic juvenile arthritis

(2019) Vivian E Saper et al.   ANNALS OF THE RHEUMATIC DISEASES

Innately adaptive or truly autoimmune

(2019) Christoph Kessel et al.   Arthritis & Rheumatology

Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease: Characterization and Risk Factors

(2019) Grant S. Schulert et al.   Arthritis & Rheumatology

Impact of IL1RN variants on response to interleukin‐1 blocking therapy in systemic juvenile idiopathic arthritis

(2019) Claas Hinze et al.   Arthritis & Rheumatology

IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis

(2018) Victoria L. Arthur et al.   Arthritis & Rheumatology

Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus

(2018) Alberto Martini et al.   JOURNAL OF RHEUMATOLOGY

2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborat

(2016) Angelo Ravelli et al.   Arthritis & Rheumatology

Sambamba: fast processing of NGS alignment formats

(2015) Artem Tarasov et al.   BIOINFORMATICS

Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis

(2015) Peter A. Nigrovic   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis

(2015) Michael J. Ombrello et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis?

(2014) Peter A. Nigrovic   Arthritis & Rheumatology

Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study

(2013) S.H. Kardaun et al.   BRITISH JOURNAL OF DERMATOLOGY

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effectiveness of First-Line Treatment With Recombinant Interleukin-1 Receptor Antagonist in Steroid-Naive Patients With New-Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

(2013) Sebastiaan J. Vastert et al.   Arthritis & Rheumatology

Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS)

(2012) Kohei Ogawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis

(2012) Yukiko Kimura et al.   ARTHRITIS CARE & RESEARCH

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions

(2011) Elizabeth D. Mellins et al.   Nature Reviews Rheumatology

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH